A Fusion Protein Consisting of the Vaccine Adjuvant Monophosphoryl Lipid A and the Allergen Ovalbumin Boosts Allergen-Specific Th1, Th2, and Th17 Responses in Vitro

Journal of Immunology Research

Volumn 2016, Issue , 2016, Pages

  Schülke, Stefan ^a   Vogel, Lothar ^a   Junker, Ann Christine ^a   Hanschmann, Kay Martin ^a   Flaczyk, Adam ^a   Vieths, Stefan ^a   Scheurer, Stephan ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; OVALBUMIN; PHOSPHORYL LIPID A; PHOSPHORYL LIPID A OVALBUMIN FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ALLERGEN; CYTOKINE; IMMUNOLOGICAL ADJUVANT; LIPID A; VACCINE;

ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; COCULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; LIGHT SCATTERING; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; ANALOGS AND DERIVATIVES; GENETICS; HUMAN; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; COCULTURE TECHNIQUES; CYTOKINES; HUMANS; LIPID A; OVALBUMIN; RECOMBINANT FUSION PROTEINS; TH1 CELLS; TH17 CELLS; TH2 CELLS; VACCINES;

EID: 84975267577     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2016/4156456     Document Type: Article

References (26)

1. J. L. Justicia, V. Cardona, P. Guardia et al., "Validation of the first treatment-specific questionnaire for the assessment of patient satisfaction with allergen-specific immunotherapy in allergic patients: the ESPIA questionnaire, " Journal of Allergy and Clinical Immunology, vol. 131, no. 6, pp. 1539-1546. e2, 2013.
2. R. Valenta, "The future of antigen-specific immunotherapy of allergy, " Nature Reviews Immunology, vol. 2, pp. 446-453, 2002.
3. D. Toussi and P. Massari, "Immune adjuvant effect of molecularly-defined toll-like receptor ligands, " Vaccines, vol. 2, no. 2, pp. 323-353, 2014.
4. J. T. Ulrich and K. R. Myers, "Monophosphoryl lipid A as an adjuvant. Past experiences and new directions, " Pharmaceutical Biotechnology, vol. 6, pp. 495-524, 1995.
5. M. Kundi, "New hepatitis B vaccine formulated with an improved adjuvant system, " Expert Review of Vaccines, vol. 6, no. 2, pp. 133-140, 2007.
6. S. T. Agnandji, B. Lell, S. S. Soulanoudjingar et al., "First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children, " The New England Journal of Medicine, vol. 365, pp. 1863-1875, 2011.
7. B. Romanowski, P. C. de Borba, P. S. Naud et al., "Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6. 4 years, " The Lancet, vol. 374, no. 9706, pp. 1975-1985, 2009.
8. P. Patel and A. M. F. Salapatek, "Pollinex- quattro: a novel and well-tolerated, ultra short-course allergy vaccine, " Expert Review of Vaccines, vol. 5, no. 5, pp. 617-629, 2006.
9. C. R. Casella and T. C. Mitchell, "Putting endotoxin to work for us: monophosphoryl lipid a as a safe and effective vaccine adjuvant, " Cellular and Molecular Life Sciences, vol. 65, no. 20, pp. 3231-3240, 2008.
10. N. Mothes, M. Heinzkill, K. J. Drachenberg et al., "Allergenspecific immunotherapy with a monophosphoryl lipid Aadjuvanted vaccine: Reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies, " Clinical and Experimental Allergy, vol. 33, no. 9, pp. 1198-1208, 2003.
11. P. Baldrick, D. Richardson, G. Elliott, and A. W. Wheeler, "Safety evaluation ofmonophosphoryl lipidA(MPL): an immunostimulatory adjuvant, " Regulatory Toxicology and Pharmacology, vol. 35, no. 3, pp. 398-413, 2002.
12. S. Schülke, A. Flaczyk, L. Vogel et al., "MPLA shows attenuated pro-inflammatory properties and diminished capacity to activatemast cells in comparison with LPS, " Allergy: European Journal of Allergy and Clinical Immunology, vol. 70, no. 10, pp. 1259-1268, 2015.
13. S. Schülke, M. Burggraf, Z. Waibler et al., "A fusion protein of flagellin and ovalbumin suppresses the TH2 response and prevents murine intestinal allergy, " Journal of Allergy and Clinical Immunology, vol. 128, no. 6, pp. 1340. e12-1348. e12, 2011.
14. H. Tighe, K. Takabayashi, D. Schwartz et al., "Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity, " Journal of Allergy and Clinical Immunology, vol. 106, no. 1 I, pp. 124-134, 2000.
15. K. Kastenmüller, U. Wille-Reece, R. W. B. Lindsay et al., "Protective T cell immunity in mice following protein-TLR7/8 agonistconjugate immunization requires aggregation, type I IFN, and multiple DC subsets, " The Journal of Clinical Investigation, vol. 121, no. 5, pp. 1782-1796, 2011.
16. L. Filí, A. Vultaggio, E. Cardilicchia et al., "A novel allergenadjuvant conjugate suitable for specific immunotherapy of respiratory allergy, " Journal of Allergy and Clinical Immunology, vol. 132, no. 1, pp. 84-92, 2013.
17. U. K. Laemmli, "Cleavage of structural proteins during the assembly of the head of bacteriophage T4, " Nature, vol. 227, no. 5259, pp. 680-685, 1970.
18. S. Schülke, Z. Waibler, M.-S. Mende et al., "Fusion protein of TLR5-ligand and allergen potentiates activation and IL-10 secretion in murine myeloid DC, " Molecular Immunology, vol. 48, no. 1-3, pp. 341-350, 2010.
19. P. N. Domadia, A. Bhunia, A. Ramamoorthy, and S. Bhattacharjya, "Structure, interactions, and antibacterial activities of MSI-594 derivedmutant peptide MSI-594F5A in lipopolysaccharide micelles: role of the helical hairpin conformation in outermembrane permeabilization, " Journal of the American Chemical Society, vol. 132, no. 51, pp. 18417-18428, 2010.
20. S. Khan, M. S. Bijker, J. J. Weterings et al., "Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells, " The Journal of Biological Chemistry, vol. 282, no. 29, pp. 21145-21159, 2007.
21. L. Knoops and J.-C. Renauld, "IL-9 and its receptor: fromsignal transduction to tumorigenesis, " Growth Factors, vol. 22, no. 4, pp. 207-215, 2004.
22. R. Rampal, A. Awasthi, and V. Ahuja, "Retinoic acid-primed human dendritic cells inhibitTh9cells and induce Th1/Th17 cell differentiation, " Journal of Leukocyte Biology, 2016.
23. G. Murugaiyan, V. Beynon, A. P. Da Cunha, N. Joller, and H. L. Weiner, "IFN- limits Th9-mediated autoimmune inflammation through dendritic cell modulation of IL-27, " The Journal of Immunology, vol. 189, no. 11, pp. 5277-5283, 2012.
24. J. D. de Boer, J. J. T. H. Roelofs, A. F. de Vos et al., "Lipopolysaccharide inhibits Th2 lung inflammation induced by house dust mite allergens in mice, " American Journal of Respiratory Cell and Molecular Biology, vol. 48, no. 3, pp. 382-389, 2013.
25. S. Soudi, A. Zavaran-Hosseini, Z. M. Hassan, M. Soleimani, F. J. Adegani, and S. M. Hashemi, "Comparative study of the effect of LPS on the function of BALB/c and C57BL/6 peritoneal macrophages, " Cell Journal, vol. 15, no. 1, pp. 45-54, 2013.
26. F. Puggioni, S. R. Durham, and J. N. Francis, "Monophosphoryl lipid A (MPL-)? promotes allergen-induced immune deviation in favour of Th1 responses, " Allergy: European Journal of Allergy and Clinical Immunology, vol. 60, no. 5, pp. 678-684, 2005.